Dec. 6 at 6:07 AM
$TNXP
Future Outlook for Medicare Patients: Roughly 50% of diagnosed fibromyalgia patients are covered by Medicare. Analysts anticipate that expanded commercial and Medicare access might become a significant "inflection point" around mid-2026, as coverage decisions are implemented and patient assistance programs can be better navigated. The Medicare Prescription Payment Plan, which caps out-of-pocket costs at
$2,000 annually starting in 2025, may eventually benefit this population.
-Google AI
Keep in mind that's HALF of people with fibromyalgia have Medicare. That
$2000 cap yearly should lay to rest some of the concerns for investors as far as the price of Tonmya (approx
$1900 mo.) goes provided it receives approval through most part D plans which i believe will most likely happen. Not financial advice.
